ClinicalTrials.gg
CompletedNCT03936335Updated Sep 28, 2026

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

An observational study in Adverse Pregnancy Outcomes and Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Regeneron Pharmaceuticals · Observational

How we know · 3 judgments

Updated Sep 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
12,343
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals — 1 open to participants now, 2 under way, none of them phase 3. Dermatitis, Atopic · Regeneron Pharmaceuticals.

Started
2019
the only one that year
Observational
5 of 30
none open now
Registered
24th of 30
by date

Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the only one that started in 2019, is one of 5 observational ones, and was the 24th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs], small for gestational age [SGA]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.

03

Conditions studied

  • Adverse Pregnancy Outcomes
  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult women with AD who are pregnant between 01 April 2017 and 31 March 2024 (with the start of pregnancy to be defined by the estimated last menstrual period (LMP))

Eligibility criteria

Key Inclusion Criteria:

  • Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP
  • Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy

Note: Other Protocol Defined Inclusion / Exclusion Criteria Apply

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
12,343 participants (actual)
Patient registry
No

Groups and cohorts

  • Dupilumab cohort

    Exposed to dupilumab during the relevant exposure window: * First trimester * Pregnancy

    Drug: dupilumab

  • Other systemic therapy or phototherapy cohort

    Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window: * First trimester * Pregnancy

  • Unexposed cohort

    * Not exposed to systemic medications (including dupilumab) or phototherapy; and * Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window: * First trimester * Pregnancy

Interventions

  • No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.

    Also known as: REGN668, Dupixent®, SAR23189

06

What researchers measure

Primary outcomes

  1. Prevalence of MCMs

    Initially identified through the presence of corresponding codes on the insurance claims, confirmed through medical record review for infant outcomes: 01 April 2017 through December 2024

    Time frame: Up to 21 months

Secondary outcomes

  1. Incidence of spontaneous abortion or miscarriage

    Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024

    Time frame: Up to 9 months

  2. Incidence of stillbirth

    Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024

    Time frame: Up to 9 months

  3. Incidence of SGA

    Identified through the presence of corresponding codes on the insurance claims for infant outcomes: 01 April 2017 through December 2024

    Time frame: Up to 21 months

07

Study locations

1 site
  • Regeneron Research Site
    Boston, Massachusetts 02215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2019 to primary completion in Apr 2026, 78 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jan 2027 → Apr 2026 and completion Jan 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2019
First posted
May 3, 2019
StartActual
Sep 30, 2019
Primary completionActual
Apr 13, 2026was Jan 2027
CompletionActual
Apr 13, 2026was Jan 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 28, 2026
Primary completion
Jan 21, 2027→Apr 13, 2026 (actual)
Sep 28, 2026
Study completion
Jan 21, 2027→Apr 13, 2026 (actual)
Sep 28, 2026
Enrollment
3930 (estimated)→12343 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Completed
    Primary completion Jan 21, 2027→Apr 13, 2026 (now actual)
    Study completion Jan 21, 2027→Apr 13, 2026 (now actual)
    Enrollment 3930 (estimated)→12343 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03936335
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 3, 2019
Start date
Sep 30, 2019
Primary completion
Apr 13, 2026
Completion
Apr 13, 2026
Last update
Sep 28, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion